Aurobindo Pharma Latest News

  1. The company’s Meropenem injection is a generic equivalent of AstraZeneca Pharmaceuticals’ Merrem Injection
    Date:28-03-2017
  2. The company’s Meropenem injection is a generic equivalent of AstraZeneca Pharmaceuticals’ Merrem Injection
    Date:28-03-2017
  3. The approved product has an estimated market size of $235 million for the twelve months ending December 2016
    Date:21-03-2017
  4. The approved product has an estimated market size of $235 million for the twelve months ending December 2016
    Date:21-03-2017
  5. Aurobindo Pharma has informed about Transcript of earnings call.

    The above information is a part of company’s filings submitted to BSE....

    Date:24-02-2017
  6. Venlafaxine hydrochloride extended-release capsules are indicated for the treatment of major depressive disorder
    Date:23-02-2017
  7. Venlafaxine hydrochloride extended-release capsules are indicated for the treatment of major depressive disorder
    Date:23-02-2017
  8. Aurobindo Pharma has informed about Presentation to the Investors / Analysts.

    The above information is a part of company’s filings submitted to BSE....

    Date:22-02-2017
  9. Total income of the company increased by 11.41% at Rs 3914.10 crore for the quarter under review
    Date:10-02-2017
  10. TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally
    Date:10-02-2017
Return to Top
Connect with us Facebook
Connect with us Facebook
Connect with us Linkedin
Connect with us Pintrest
Connect with us Google Plus
Connect with us You Tube
Connect with us Mobile App
Request a Call Back
We will guide you on how to find
the Right stocks at the Right prices.
Mobile
Invalid Mobile Number
x
Thank you for
contacting us.
We will call you
shortly.